Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Discovery of widespread type I and type V CRISPR-Cas inhibitors.

Literature DB >> 30190308

Discovery of widespread type I and type V CRISPR-Cas inhibitors.

Nicole D Marino¹, Jenny Y Zhang¹, Adair L Borges¹, Alexander A Sousa^2,3,4, Lina M Leon¹, Benjamin J Rauch¹, Russell T Walton^2,3,4, Joel D Berry¹, J Keith Joung^2,3,4,5, Benjamin P Kleinstiver^2,3,4,5, Joseph Bondy-Denomy^6,7.

Abstract

Bacterial CRISPR-Cas systems protect their host from bacteriophages and other mobile genetic elements. Mobile elements, in turn, encode various anti-CRISPR (Acr) proteins to inhibit the immune function of CRISPR-Cas. To date, Acr proteins have been discovered for type I (subtypes I-D, I-E, and I-F) and type II (II-A and II-C) but not other CRISPR systems. Here, we report the discovery of 12 acr genes, including inhibitors of type V-A and I-C CRISPR systems. AcrVA1 inhibits a broad spectrum of Cas12a (Cpf1) orthologs-including MbCas12a, Mb3Cas12a, AsCas12a, and LbCas12a-when assayed in human cells. The acr genes reported here provide useful biotechnological tools and mark the discovery of acr loci in many bacteria and phages.

Entities: Chemical

Mesh：

Substances：

Year: 2018 PMID： 30190308 PMCID： PMC6520112 DOI： 10.1126/science.aau5174

Source DB: PubMed Journal: Science ISSN： 0036-8075 Impact factor: 47.728

25 in total

1. Theoretical foundation of the balanced minimum evolution method of phylogenetic inference and its relationship to weighted least-squares tree fitting.

Authors: Richard Desper; Olivier Gascuel
Journal: Mol Biol Evol Date: 2003-12-23 Impact factor: 16.240

2. COBALT: constraint-based alignment tool for multiple protein sequences.

Authors: Jason S Papadopoulos; Richa Agarwala
Journal: Bioinformatics Date: 2007-03-01 Impact factor: 6.937

3. The CRISPR/Cas adaptive immune system of Pseudomonas aeruginosa mediates resistance to naturally occurring and engineered phages.

Authors: Kyle C Cady; Joe Bondy-Denomy; Gary E Heussler; Alan R Davidson; George A O'Toole
Journal: J Bacteriol Date: 2012-08-10 Impact factor: 3.490

Discovery of widespread type I and type V CRISPR-Cas inhibitors.

1. Theoretical foundation of the balanced minimum evolution method of phylogenetic inference and its relationship to weighted least-squares tree fitting.

2. COBALT: constraint-based alignment tool for multiple protein sequences.

3. The CRISPR/Cas adaptive immune system of Pseudomonas aeruginosa mediates resistance to naturally occurring and engineered phages.

4. Moraxella bovoculi sp. nov., isolated from calves with infectious bovine keratoconjunctivitis.

5. FLASH assembly of TALENs for high-throughput genome editing.

6. Cost-effective, high-throughput DNA sequencing libraries for multiplexed target capture.

7. The HHpred interactive server for protein homology detection and structure prediction.

8. A new group of phage anti-CRISPR genes inhibits the type I-E CRISPR-Cas system of Pseudomonas aeruginosa.

9. Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing.

10. Bacteriophage genes that inactivate the CRISPR/Cas bacterial immune system.

1. Listeria Phages Induce Cas9 Degradation to Protect Lysogenic Genomes.

2. Structural insight into multistage inhibition of CRISPR-Cas12a by AcrVA4.

Review 3. Structure-based functional mechanisms and biotechnology applications of anti-CRISPR proteins.

4. Anti-CRISPR-Associated Proteins Are Crucial Repressors of Anti-CRISPR Transcription.

5. Diverse Mechanisms of CRISPR-Cas9 Inhibition by Type IIC Anti-CRISPR Proteins.

6. CRISPR-Cas13 Inhibitors Block RNA Editing in Bacteria and Mammalian Cells.

Review 7. Three New Cs for CRISPR: Collateral, Communicate, Cooperate.

Review 8. Precision Control of CRISPR-Cas9 Using Small Molecules and Light.

9. Machine learning predicts new anti-CRISPR proteins.

10. A phage-encoded anti-CRISPR enables complete evasion of type VI-A CRISPR-Cas immunity.